spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  Innocoll 

Devices Distribution

 News Release - April 4, 2006

Innocoll Announces Additional Distribution Arrangements in the Middle East and the Commonwealth of Independent States for CollaRx GENTAMICIN SURGICAL IMPLANT

ASHBURN, Va., April 4 (HSMN NewsFeed) -- Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed distribution arrangements for its CollaRx GENTAMICIN SURGICAL IMPLANT in Iraq, Iran, Syria, Kazakhstan, Azerbaijan, Georgia, Uzbekistan, Tajikistan and Turkmenistan.

The product is indicated for the treatment and prevention of post- operative acquired infection. Innocoll, Inc. acquired the product rights from Essex Chemis AG, an affiliated company of Schering-Plough Corporation (NYSE: SGP ) and has since assumed all sales, marketing and distribution activities for the product.

Dr. Michael Myers, President and CEO of Innocoll, Inc., stated, "These arrangements bring us closer to our goal of gaining complete market coverage for this product across the continent of Europe, through the Middle East and into Asia, as we continue to ramp-up our direct sales activities in Western Europe."

The product was developed using Innocoll's proprietary collagen-based technology, CollaRx(TM), and has been approved in over 50 countries. It is marketed under the following different trade names (COLLATAMP® G, COLLATAMP® EG, SULMYCIN® IMPLANT, GARAMYCIN® SCHWAMM, DURACOL®, DURACOLL®, GENTACOL®, GENTACOLL®, GARACOL®, GARACOLL®, CRONOCOL®) in Europe, Central and South America, Russia, the Middle East, Africa and Asia.

About GENTAMICIN SURGICAL IMPLANT

GENTAMICIN SURGICAL IMPLANT is a biodegradable leave-behind implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin, and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. It is based on Innocoll's CollaRx(TM) technology, a proprietary collagen-based system which locally delivers a wide variety of drug products, and can be formulated for implantable or topical application as a lyophilized sponge or as a cast film.

About Innocoll, Inc.

Innocoll is a privately held, fully integrated, global, hospital specialty pharmaceutical company specializing in surgical and dermatological products. It develops and markets internationally a range of medical products using its proprietary collagen-based technologies, CollaRx(TM) and LiquiColl®. For more information, please visit http://www.Innocoll.com. For product or pipeline information, please visit http://www.Innocoll-pharma.com.

Source: Innocoll

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Innocoll 
Search: CollaRx 
Search: GENTAMICIN SURGICAL IMPLANT 

 Related News Items

Innocoll and DURECT Announce U.S. launch of POSIMIR(R)

Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.